ORBIMED ADVISORS LLC Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001055951

What is a 13F filing? Who files one and when · What 13F filings can't tell you

MidHealth TiltHigh Turnover how tags are computed

Q3 2026 · 112 positions · Total reported value $4.91B · Top-10 concentration 51.1% · Updated 2026-11-17

Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR

Turnover: 62.8% · 26 new · 32 cut · 33 exited

Active Share (vs S&P 500): 95.4% · vs QQQ: 99.0% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q2 2026 → Q3 2026): -11.1% · vs SPY -13.2% · Prev Value $4.97B — last quarter positions weighted by this quarter price moves · ranking

Est. QTD Return (Q3 2026 → newest close): -4.2% · vs SPY -6.3% · Latest Value $4.91B — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking

In its Q3 2026 13F filing, ORBIMED ADVISORS LLC disclosed 112 equity positions with a combined reported value of $4.91B. The filing implies a moderately concentrated portfolio: its ten largest positions account for 51.1% of reported value. HoldingsHub classifies the profile as Mid / Health Tilt / High Turnover.

The largest disclosed positions as of Q3 2026 were EWTX ($630.05M), VNDA ($482.66M), ELVN ($310.64M). By sector, the heaviest allocations are Health Care 91.9%, Industrials 2.2%. Versus the prior quarter, allocation shifted toward Industrials (+0.7pp) and away from Other (-0.6pp).

Versus the prior quarter, ORBIMED ADVISORS LLC opened 26 new positions, trimmed 32 and fully exited 33, a turnover rate of 62.8% of positions. The portfolio's overlap with the prior quarter was 59% of names.

The largest new positions opened in Q3 2026 were VNDA ($482.66M), GRTX ($77.46M), ABBV ($67.91M).

Of the 33 positions fully exited versus the prior quarter, the largest were DYN ($71.86M), CGON ($69.12M), BSX ($63.30M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q3 2026)

  • VNDA VANDA PHARMACEUTICALS INC · $482.66M
  • GRTX ELECTRA THERAPEUTICS INC · $77.46M
  • ABBV ABBVIE INC · $67.91M
  • CDNA CAREDX INC · $60.76M
  • ABT ABBOTT LABORATORIES · $57.22M
  • JAZZ JAZZ PHARMACEUTICALS PLC · $30.35M
  • ARTV ARTIVA BIOTHERAPEUTICS INC · $27.98M
  • CELC CELCUITY INC · $25.01M

Fully Exited (vs previous quarter)

  • DYN DYNE THERAPEUTICS INC · prev qtr: $71.86M
  • CGON CG ONCOLOGY INC · prev qtr: $69.12M
  • BSX BOSTON SCIENTIFIC CORP · prev qtr: $63.30M
  • XENE XENON PHARMACEUTICALS INC · prev qtr: $53.87M
  • BMY BRISTOL-MYERS SQUIBB CO · prev qtr: $53.30M
  • SYK STRYKER CORPORATION · prev qtr: $50.09M
  • XBI SPDR SERIES TRUST · prev qtr: $47.48M
  • CRNX CRINETICS PHARMACEUTICALS IN · prev qtr: $37.38M

Insider Transactions (Form 4)

Latest ORBIMED ADVISORS LLC buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

Transaction date Activity Security Shares Price Filing
2026-11-10 Buy Electra Therapeutics, Inc. 2,000 $8.45 SEC filing
2026-11-10 Buy Electra Therapeutics, Inc. 20,700 $8.45 SEC filing
2026-11-09 Buy Electra Therapeutics, Inc. 16,000 $8.24 SEC filing
2026-11-09 Buy Electra Therapeutics, Inc. 4,000 $8.24 SEC filing
2026-11-06 Buy Electra Therapeutics, Inc. 39,600 $7.85 SEC filing
2026-11-06 Buy Electra Therapeutics, Inc. 9,816 $7.85 SEC filing
2026-11-05 Buy Electra Therapeutics, Inc. 125,200 $7.31 SEC filing
2026-11-05 Buy Electra Therapeutics, Inc. 30,891 $7.31 SEC filing

All insider transactions →

Fund Profile

ORBIMED ADVISORS LLC is a New York-based investment firm founded by Samuel Isen and others, specializing in healthcare and life sciences investing.

Investment Approach

ORBIMED employs a long-term investment strategy focused on the healthcare and life sciences sectors. The firm has over 30 years of industry experience and identifies investment opportunities globally.

Asset Classes

ORBIMED invests across multiple asset classes including public equity (as evidenced by their SEC 13F filings), private equity, debt instruments, venture capital, and special situations/distressed debt.

Key People

Samuel Isen - Co-founder and Managing Partner

Steven Bloom - Co-founder and Managing Partner

The firm also has several other managing partners and investment professionals

Notable Facts

ORBIMED is one of the largest healthcare-focused investment firms, with offices in multiple cities including New York, Boston, San Francisco, London, and Hong Kong.

This information is based on public disclosures; investment decisions should reference official filings.

AI Rebalance Analysis

1. Overall direction and market view: The fund increased positions (26 new) and total value, with a focus on Health Care (100% of top-10). Weight changes suggest tactical adjustments rather than broad sector rotation. 2. Key moves: - Added: MRK (+42.6% shares, weight +1.09pp). - Reduced: MBX (-10.3% shares, weight -0.14pp). - New: VNDA (9.82% weight). 3. Portfolio structure: Active, concentrated (112 positions), high Health Care bias. Risk appetite appears moderate, with mix of large caps (LLY, MRK) and biotech (EWTX, ELVN). 4. Per-holding one-liner: - EWTX: Biotech (unverified). - VNDA: Neurology-focused pharma (unverified). - ELVN: Biotech (unverified). - LLY: Large-cap pharma. - SVA: Vaccines (unverified). - MBX: Biotech (unverified). - MRK: Large-cap pharma. - GH: Cancer diagnostics (unverified). - AVBP: Biotech (unverified). - CRVS: Oncology biotech (unverified). 5. Style summary: Tactically added Merck while trimming a small biotech, expanding into new biotech names within a concentrated, Health Care-focused active strategy.

Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice. · AI generated 2026-11-17 09:41

Sector Allocation

Health Care 91.9%
Other 5.6%
Sort by: Value · CSV
# Shares Value Weight Allocation Change
1 15.52M $630.05M 12.82%
12.82%
Hold
2 24.21M $482.66M 9.82%
9.82%
New
3 6.78M $310.64M 6.32%
6.32%
Hold
4 257.90K $298.41M 6.07%
6.07%
Hold
5 2.72M $195.50M 3.98%
3.98%
Hold
6 3.07M $180.25M 3.67%
3.67%
Reduce
7 946.10K $137.48M 2.80%
2.80%
Add
8 584.10K $104.18M 2.12%
2.12%
Hold
9 3.03M $91.67M 1.86%
1.86%
Hold
10 7.17M $82.54M 1.68%
1.68%
Hold
11 199.70K $82.54M 1.68%
1.68%
Reduce
12 3.12M $82.52M 1.68%
1.68%
Add
13 120.40K $81.28M 1.65%
1.65%
Add
14 219.00K $80.39M 1.64%
1.64%
Add
15 345.20K $78.65M 1.60%
1.60%
Add
16 6.89M $77.46M 1.58%
Form 4 · 22 →
1.58%
New
17 75.18K $72.09M 1.47%
1.47%
Reduce
18 834.90K $72.07M 1.47%
1.47%
Hold
19 259.60K $67.91M 1.38%
1.38%
New
20 2.19M $67.17M 1.37%
1.37%
Reduce
21 3.00M $66.69M 1.36%
1.36%
Hold
22 2.00M $64.16M 1.31%
1.31%
Add
23 379.30K $61.78M 1.26%
1.26%
Reduce
24 934.80K $60.76M 1.24%
1.24%
New
25 200.40K $58.36M 1.19%
1.19%
Reduce
26 579.00K $57.22M 1.16%
1.16%
New
27 127.80K $48.76M 0.99%
0.99%
Reduce
28 6.31M $43.01M 0.88%
0.88%
Hold
29 1.33M $41.62M 0.85%
0.85%
Reduce
30 988.49K $40.16M 0.82%
0.82%
Add
31 96.80K $39.36M 0.80%
0.80%
Reduce
32 408.00K $38.85M 0.79%
0.79%
Add
33 1.45M $36.55M 0.74%
0.74%
Reduce
34 8.29M $35.72M 0.73%
0.73%
Hold
35 4.13M $34.14M 0.69%
0.69%
Hold
36 97.70K $32.49M 0.66%
0.66%
Add
37 229.86K $31.70M 0.65%
0.65%
Add
38 170.88K $31.51M 0.64%
0.64%
Add
39 131.10K $30.35M 0.62%
0.62%
New
40 5.69M $30.01M 0.61%
0.61%
Hold
41 80.18K $29.73M 0.60%
0.60%
Add
42 1.40M $29.04M 0.59%
0.59%
Add
43 1.68M $27.98M 0.57%
0.57%
New
44 314.50K $25.01M 0.51%
0.51%
New
45 278.00K $23.99M 0.49%
0.49%
New
46 384.52K $23.28M 0.47%
0.47%
Reduce
47 5.68M $22.21M 0.45%
0.45%
Hold
48 150.00K $21.13M 0.43%
0.43%
Add
49 1.56M $20.96M 0.43%
0.43%
Reduce
50 3.33M $20.93M 0.43%
0.43%
Hold

FAQ

What did ORBIMED ADVISORS LLC buy in 2026-Q3?

In its 2026-Q3 13F filing, ORBIMED ADVISORS LLC reported 112 equity positions worth $4.91B in aggregate; its largest disclosed positions were EWTX ($630.05M), VNDA ($482.66M), ELVN ($310.64M).

How large is ORBIMED ADVISORS LLC's portfolio?

ORBIMED ADVISORS LLC reported $4.91B of long equity holdings across 112 positions as of 2026-Q3. Top-10 holdings account for 51.1% of reported value.

What is ORBIMED ADVISORS LLC's investment style?

HoldingsHub classifies the portfolio as Mid / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/orbimed-advisors/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →